Cargando…

Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide. Currently, the only strategy for palliative treatment of AD is to inhibit acetylcholinesterase (AChE) in order to increase the concentration of acetylcholine in the synaptic cleft. Evidence indicates that AChE also...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantoani, Susimaire P., Chierrito, Talita P. C., Vilela, Adriana F. L., Cardoso, Carmen L., Martínez, Ana, Carvalho, Ivone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6273213/
https://www.ncbi.nlm.nih.gov/pubmed/26861273
http://dx.doi.org/10.3390/molecules21020193
_version_ 1783377332154662912
author Mantoani, Susimaire P.
Chierrito, Talita P. C.
Vilela, Adriana F. L.
Cardoso, Carmen L.
Martínez, Ana
Carvalho, Ivone
author_facet Mantoani, Susimaire P.
Chierrito, Talita P. C.
Vilela, Adriana F. L.
Cardoso, Carmen L.
Martínez, Ana
Carvalho, Ivone
author_sort Mantoani, Susimaire P.
collection PubMed
description Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide. Currently, the only strategy for palliative treatment of AD is to inhibit acetylcholinesterase (AChE) in order to increase the concentration of acetylcholine in the synaptic cleft. Evidence indicates that AChE also interacts with the β-amyloid (Aβ) protein, acting as a chaperone and increasing the number and neurotoxicity of Aβ fibrils. It is known that AChE has two binding sites: the peripheral site, responsible for the interactions with Aβ, and the catalytic site, related with acetylcholine hydrolysis. In this work, we reported the synthesis and biological evaluation of a library of new tacrine-donepezil hybrids, as a potential dual binding site AChE inhibitor, containing a triazole-quinoline system. The synthesis of hybrids was performed in four steps using the click chemistry strategy. These compounds were evaluated as hAChE and hBChE inhibitors, and some derivatives showed IC(50) values in the micro-molar range and were remarkably selective towards hAChE. Kinetic assays and molecular modeling studies confirm that these compounds block both catalytic and peripheral AChE sites. These results are quite interesting since the triazole-quinoline system is a new structural scaffold for AChE inhibitors. Furthermore, the synthetic approach is very efficient for the preparation of target compounds, allowing a further fruitful new chemical library optimization.
format Online
Article
Text
id pubmed-6273213
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62732132018-12-28 Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors Mantoani, Susimaire P. Chierrito, Talita P. C. Vilela, Adriana F. L. Cardoso, Carmen L. Martínez, Ana Carvalho, Ivone Molecules Article Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide. Currently, the only strategy for palliative treatment of AD is to inhibit acetylcholinesterase (AChE) in order to increase the concentration of acetylcholine in the synaptic cleft. Evidence indicates that AChE also interacts with the β-amyloid (Aβ) protein, acting as a chaperone and increasing the number and neurotoxicity of Aβ fibrils. It is known that AChE has two binding sites: the peripheral site, responsible for the interactions with Aβ, and the catalytic site, related with acetylcholine hydrolysis. In this work, we reported the synthesis and biological evaluation of a library of new tacrine-donepezil hybrids, as a potential dual binding site AChE inhibitor, containing a triazole-quinoline system. The synthesis of hybrids was performed in four steps using the click chemistry strategy. These compounds were evaluated as hAChE and hBChE inhibitors, and some derivatives showed IC(50) values in the micro-molar range and were remarkably selective towards hAChE. Kinetic assays and molecular modeling studies confirm that these compounds block both catalytic and peripheral AChE sites. These results are quite interesting since the triazole-quinoline system is a new structural scaffold for AChE inhibitors. Furthermore, the synthetic approach is very efficient for the preparation of target compounds, allowing a further fruitful new chemical library optimization. MDPI 2016-02-05 /pmc/articles/PMC6273213/ /pubmed/26861273 http://dx.doi.org/10.3390/molecules21020193 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mantoani, Susimaire P.
Chierrito, Talita P. C.
Vilela, Adriana F. L.
Cardoso, Carmen L.
Martínez, Ana
Carvalho, Ivone
Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors
title Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors
title_full Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors
title_fullStr Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors
title_full_unstemmed Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors
title_short Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors
title_sort novel triazole-quinoline derivatives as selective dual binding site acetylcholinesterase inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6273213/
https://www.ncbi.nlm.nih.gov/pubmed/26861273
http://dx.doi.org/10.3390/molecules21020193
work_keys_str_mv AT mantoanisusimairep noveltriazolequinolinederivativesasselectivedualbindingsiteacetylcholinesteraseinhibitors
AT chierritotalitapc noveltriazolequinolinederivativesasselectivedualbindingsiteacetylcholinesteraseinhibitors
AT vilelaadrianafl noveltriazolequinolinederivativesasselectivedualbindingsiteacetylcholinesteraseinhibitors
AT cardosocarmenl noveltriazolequinolinederivativesasselectivedualbindingsiteacetylcholinesteraseinhibitors
AT martinezana noveltriazolequinolinederivativesasselectivedualbindingsiteacetylcholinesteraseinhibitors
AT carvalhoivone noveltriazolequinolinederivativesasselectivedualbindingsiteacetylcholinesteraseinhibitors